NDA 021385 · Lacer Pharma
Ertaczo
Sertaconazole Nitrate · Topical
NovelLast checked: Nov 19, 2026Latest source record: Dec 17, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Dec 10, 2003
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
1 Phase 3, 0 recruiting
FAERS reports
162
124 serious, 21 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 7, 2026.
ERTACZO ® cream, 2%, is indicated for the topical treatment of interdigital tinea pedis in immunocompetent adult and pediatric patients 12 years of age and older caused by Trichophyton rubrum , Trichophyton mentagrophytes, and Epidermophyton floccosum . ERTACZO cream, 2% is an azole antifungal indicated for the topical treatment of interdigital tinea pedis in immunocompetent adult and pediatric patients 12 years of age and older caused by Trichophyton rubrum, Trichophyton mentagrophytes , and Epidermophyton floccosum . ( 1 )
Mechanism: Sertaconazole nitrate is an azole antifungal [see Clinical Pharmacology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ERTACZO · SERTACONAZOLE NITRATE 2% · CREAM, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sertaconazole Nitrate" as an intervention, any sponsor and status, largest first.
- Efficacy of Tropical Sertaconazole Nitrate 2% Vs Clotrimazole 1% for Tinea PedisPivotal-lookingNot yet recruiting
Jinnah Postgraduate Medical CentreGovernment (non-federal)
NCT06869681 · 100 participants (planned) · Start Mar 1, 2025 · Primary completion May 30, 2025
Drug: Topical Sertaconazole 2%; Clotrimazole 1% · For: Tinea Pedis
Spirig Pharma Ltd.Industry
NCT01792713 · 70 participants · Start Feb 2013 · Primary completion Sep 2013
Drug: Sertaconazole 2% cream; Placebo · For: Skin Alterations Associated With Atopic Dermatitis
Sites: Berlin, Germany; Münster, Germany
- Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and FemalesPivotal-lookingStatus unknown
Jamaica Hospital Medical CenterAcademic, hospital or other
NCT00856596 · 30 participants (planned) · Start Mar 2009 · Primary completion Aug 2009
Drug: Sertaconazole nitrate cream 2% · For: Tinea Pedis; Athlete's Foot; Foot Fungus and 1 more
Sites: Jamaica, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue15
- off label use15
- urethral valves14
- fall13
- rash12
- weight decreased11
- asthenia10
- gait disturbance10
- nausea10
- dizziness9
- erythema9
- pruritus9
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 10 |
| 2014 | 1 |
| 2016 | 6 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 6 |
| 2020 | 2 |
| 2021 | 8 |
| 2022 | 27 |
| 2023 | 26 |
| 2024 | 25 |
| 2025 | 16 |
| 2026 | 13 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ertaczo (Sertaconazole Nitrate)
2024 spending
$4.9M
Beneficiaries
1,663
4,137 claims
Per beneficiary
$2,957
$14.06 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $429,250 |
| 2021 | $296,437 |
| 2022 | $301,496 |
| 2023 | $941,806 |
| 2024 | $4,917,777 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- An open-label study of the safety and efficacy of sertaconazole nitrate in the treatment of seborrheic dermatitis.
Elewski BE, Cantrell WC · J Drugs Dermatol 2011 · Clinical Trial, Research Support, Non-U.S. Gov't
- Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments.
Rotta I, Ziegelmann PK, Otuki MF, et al. · JAMA Dermatol 2013 · Comparative Study, Meta-Analysis
- Safety and efficacy of sertaconazole nitrate cream 2% in the treatment of tinea pedis interdigitalis: a subgroup analysis.
Borelli C, Korting HC, Bödeker RH, et al. · Cutis 2010 · Multicenter Study, Randomized Controlled Trial
- The safety and efficacy of sertaconazole nitrate cream 2% for tinea pedis.
Savin R, Jorizzo J · Cutis 2006 · Multicenter Study, Randomized Controlled Trial
- Efficacy and tolerability of sertaconazole nitrate 2% cream vs. miconazole in patients with cutaneous dermatophytosis.
Sharma A, Saple DG, Surjushe A, et al. · Mycoses 2011 · Clinical Trial, Phase IV, Comparative Study
- [Evaluation of the efficacity and speed of action of sertaconazole nitrate suppository and cream combined treatment for vulvovaginal candidiasis].
Quereux C, Gelas B, Chevallier T, et al. · Gynecol Obstet Fertil 2000 · Clinical Trial, English Abstract
Sponsor: Lacer Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.